Roche Holding AG has recently received a consensus rating of 'Hold' from several brokerages. In the meantime, UBS has upgraded its rating for Roche to 'Buy,' and increased its target to CHF338. Also, reports show
RHHBY's 9% sales growth in Q3 2024, which was largely achieved due to expanding AI in
Digital Pathology and
Drug Development. Roche is also in focus for completing a
$1.5 billion acquisition of the biopharma company, Poseida, and has seen success with a 66% share tender. However, there are concerns about the side effects of its obesity pill, which have impacted its share prices. Amidst these, Roche has received
CE Mark for an ovarian cancer diagnostic test and successfully completed a tender offer for Poseida Therapeutics' shares. Another highlight includes Roche's Q4 2024 sales and earnings beat due to the strong performance of its key drugs. Yet, investors show concern over lower company earnings and shareholder returns as
Roche Holding stock falls a further 3.7% in past week.
Roche Stocks News Analytics from Thu, 16 May 2024 07:00:00 GMT to Sat, 15 Feb 2025 15:37:17 GMT -
Rating 5
- Innovation 6
- Information 7
- Rumor -3
